Clinical trials: Hepato Cellular Carcinoma
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Kidney (Renal Cell) Cancer
Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma
Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.
- Trial name
- NCT01326390
- Testing
- dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose…
- Trial name
- NCT07734766
- Testing
- Ebastine
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma (HCC), Sedation and Analgesia
The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC).
- Conditions
- Hepato Cellular Carcinoma (HCC), Sedation and Analgesia, Ablation Techniques
- Trial name
- NCT07657897
- Testing
- Sedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University
Liver Carcinoma, Liver Transplant
Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence
This is a retrospective study of single-center cohorts that involves patients with HCC who underwent liver transplantation between January 2016 and 2021, who received livers preserved with Hypothermic Oxygenated Perfusion (HOPE)…
- Conditions
- Liver Carcinoma, Liver Transplant, Tumor Recurrence, Hepato Cellular Carcinoma (HCC)
- Trial name
- NCT06720675
- Testing
- Hypothermic Oxygented Perfusion, Static Cold Storage
- Where
- Italy
- Volunteers
- 237 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepato Cellular Carcinoma (HCC)
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07536789
- Testing
- MRG003
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07267806
- Testing
- Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Linhui Peng
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Hepato-cellular Carcinoma
Novel Biomarker Assay for Biomarker Assay for HCC Detection
The primary purpose of this study is to assess the performance feasibility of Genetron's novel HCC liquid biopsy biomarkers assay for early detection.
- Trial name
- GTH_HCC (NCT05494853)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genetron Health
Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes The goal of this clinical trial is to evaluate of the involvement of Neutrophil extracellular traps in the evolution of…
- Conditions
- Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation, Anesthesia, Lidocaine Infusion
- Trial name
- NCT07207304
- Testing
- Anesthesia, Anesthesia induction with TCI, sevoflurane anesthesia
- Where
- Romania
- Volunteers
- 153 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepato Cellular Carcinoma
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
- Trial name
- CineDoxo (NCT03706157)
- Testing
- Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Hepato Cellular Carcinoma
IIT2025-03-YANG-LIFT-HCC
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC).
- Trial name
- NCT07489976
- Testing
- STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ju Dong Yang
Hepato Cellular Carcinoma (HCC)
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S.
- Trial name
- NCT06608940
- Testing
- BC3402, Durvalumab, Tremelimumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hepato Cellular Carcinoma (HCC), Liver Resection
Retrospective Clinical Validation of HepatoPredict
HepatoPredict is an innovative prognostic tool to support hepatologists, hepatobiliary surgeons and multidisciplinary teams in deciding on the best therapeutical approach for a patient with Hepatocellular Carcinoma, the most…
- Conditions
- Hepato Cellular Carcinoma (HCC), Liver Resection, Liver Transplantation
- Trial name
- NCT06894524
- Volunteers
- 200 people
- Sponsor
- Ophiomics
Hepatocellular Carcinoma
Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency
HCC (Hepato-cellular Carcinoma) is the fifth most frequent cancer in humans and its prevalence is growing. The most effective treatment of HCC is surgical and includes resection and liver transplantation; however, only 20% of the…
- Trial name
- HCC (NCT01322477)
- Testing
- F18-FDG PET/CT
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Hadassah Medical Organization